Iambic Therapeutics, Inc. (IAM)
NASDAQ: IAM · Real-Time Price · USD
14.67
-1.13 (-7.15%)
At close: Oct 22, 2026, 4:00 PM EDT
14.40
-0.27 (-1.84%)
Pre-market: Oct 23, 2026, 4:02 AM EDT
Iambic Therapeutics Revenue
Iambic Therapeutics had revenue of $6.38M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $18.25M. In the year 2025, Iambic Therapeutics had annual revenue of $9.43M with 689.45% growth. That makes Iambic Therapeutics the 34,308th largest company in the world by revenue and 4,513th in the United States.
Revenue (ttm)
$18.25M
Revenue Growth
+689.45%
P/S Ratio
38.10
Revenue / Employee
$106,731
Employees
171
Market Cap
695.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.43M | 8.23M | 689.45% |
| Dec 31, 2024 | 1.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
IAM News
- 7 days ago - Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics today - TheFly
- 7 days ago - AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO - TipRanks
- 7 days ago - Iambic Therapeutics opens at $16.15, IPO priced at $16.00 - TheFly
- 8 days ago - Iambic Therapeutics 9.375M share IPO priced at $16.00 - TheFly
- 14 days ago - Iambic Therapeutics Registration statement: Registration filing - Filings
- 4 weeks ago - Small molecule biotech Iambic Therapeutics files for a $100 million IPO - Renaissance Capital
- 4 weeks ago - Iambic Therapeutics IPO Registration Document (S-1) - SEC
- 4 weeks ago - Iambic Therapeutics Registration statement: Registration filing - Filings